Advancing IVF - personalised strategies: Lecture Notes

Opening Remarks & Context

• Event was an academic IVF / reproductive-medicine program featuring eminent speakers (Dr. Nagori, Dr. Alpesh Gandhi, Dr. Jayesh Amin, Dr. Bhavishi, etc.)

• Emphasis on mentorship, lifelong learning, nationwide shortage of teachers, and the need for virtual/ hybrid teaching methods.

• Transition from inaugural speeches to the scientific session focusing on IVF pregnancy characteristics, complications, and optimisation strategies.

Why IVF Pregnancies Are Considered “Different”

• Patient profile differences

• Delayed child-bearing ➔ advanced maternal age (≥$35$ y), higher BMI, PCOS, prior sub-fertility, comorbidities.

• Higher prevalence of uterine anomalies, fibroids, endocrine disease.
  • Treatment-related factors

• Ovarian stimulation (risk of OHSS, altered hormonal milieu).

• Use of donor gametes/blastocyst culture/cryopreservation.
  • Result: increased incidence of specific maternal, fetal and placental complications vs. spontaneous conceptions.

Ovarian Hyper-Stimulation Syndrome (OHSS)

• Incidence after conventional IVF:

  • Mild OHSS affects ≈ $\tfrac13$ of cycles.

  • Moderate–severe OHSS combined incidence $3.1\% – 8\%$.

• Severe OHSS ➔ ↑ risk of pregnancy-induced hypertension (PIH) & pre-term labour.

• Preventive tips

  • Individualised stimulation, agonist trigger, freeze-all, outpatient monitoring.

Miscarriage & Ectopic Risk

• Miscarriage rate after ART ≈ $15\text{–}20\%$.

  • Etiology influenced by uterine anomalies, fibroids, endocrine disorders.

  • Positive counselling point: women who miscarry after ART still have a higher live-birth probability in subsequent cycles than those who never conceived.

• Ectopic pregnancy risk ≈ $1.4\%$ per ART cycle.

  • Heterotopic pregnancy more common after double-embryo transfer ➔ always scan adnexa even when intra-uterine sac visualised.

Hypertensive Disorders of Pregnancy (HDP) in IVF

• Heightened risk of PIH, pre-eclampsia, venous thrombo-embolism (VTE).
• Risk amplifiers

• Age >35 y

• BMI >30\,\text{kg/m}^2

• PCOS

• Multiple gestation

• Use of donor oocytes/sperm/embryos.
  • Aspirin prophylaxis

• Recommend low-dose aspirin $75\text{–}150\,\text{mg}$ nightly from $12$ weeks → delivery for high-risk women.
  • Surveillance protocol for high-risk IVF pregnancies

• Maternal + fetal evaluation every $3$ wk (24–32 wk) then every $2$ wk thereafter.
  • Case vignette

• 35-y PCOS, BMI $36$. Missed follow-up, presented at 28 wk with severe pre-eclampsia (urine protein $3{+}$). Emergency management, pre-term delivery achieved good neonatal outcome due to NICU preparedness. Highlights need for strict follow-up & early antihypertensive + corticosteroid use.

Gestational Diabetes Mellitus (GDM) & VTE

• Literature inconclusive; some studies show ↑ GDM in ART.

• VTE prophylaxis: low-molecular-weight heparin generally not required unless additional risk factors.

Fetal Aneuploidy Screening & Donor-Egg Nuance

• Offer combined first-trimester screening (NT scan + dual markers).

• Egg-donor cycles: use donor’s age for age-related aneuploidy calculation, not recipient’s age.

• NIPT remains optional but gains utility in older donors or abnormal biochemical risk.

Placental & Cord Abnormalities

• Placenta praevia

• Higher when blastocyst transfer vs. cleavage-stage.

• Lower when frozen-embryo transfer vs. fresh.
  • Vasa praevia & abnormal cord insertion (velamentous, marginal) more common ➔ assess cord insertion during anatomy scan.
  • Possible link to ↑ fetal growth restriction (FGR) in IVF.

Practical Management Principles in IVF Pregnancy

1. Pre-conception counselling

   • Explain specific ART-related risks; encourage optimal BMI, control chronic disease.

2. Early, frequent antenatal visits

   • Baseline labs, dating scan, BP, weight, urine protein.

3. Targeted prophylaxis
   • Aspirin, calcium, vitamin D, thromboprophylaxis if indicated.

4. Serial growth & Doppler scans from $28$ wk (or earlier if risk factors).

5. Delivery planning

   • Elective single embryo transfer (eSET) minimises multiples & complications.

   • Timely induction/CS in severe HDP, FGR or placenta previa.

Low AMH / Poor Ovarian Reserve (POR) Session Highlights

• Anti-Müllerian Hormone (AMH)

• Secreted by $4\text{–}8$ mm follicles.

• Low AMH alone should not mandate oocyte-donation; prognosis also relies on AFC, age & previous response.
  • AFC (Antral Follicle Count)

• Considered the most reliable bedside test for oocyte yield prediction.
  • Stimulation strategies for POR

• Pre-treatment for follicular synchrony: short course oral E₂ or OCP.

• GnRH-agonist “long” or micro-flare vs. antagonist with higher FSH/hMG doses (≥$300$ IU).

• DuoStim / luteal-phase stimulation as rescue.

• Adjuvants with limited evidence (GH, androgens, CoQ10) – use judiciously.
  • Counsel about realistic oocyte yield (often ≤$3$) & cumulative live-birth; encourage oocyte/embryo cryopreservation at younger age where possible.

Laboratory & Technical Determinants of Success

• Culture environment

• HEPA-filtered air, VOC-free, temperature $37\pm0.1^{\circ}\text{C}$, pH $7.25\pm0.05$, low-oxygen $5\%$ systems.
  • Handling

• Minimise light & temperature fluctuations; rapid, atraumatic oocyte pickup.
  • Embryo Transfer (ET) technique

• Soft catheter, ultrasound guidance, avoid uterine contractions, deposit at $1.5\text{–}2\,\text{cm}$ from fundus.

Role of PGT-A & “Add-Ons”

• PGT-A may:

• Help explain repeated implantation failure when all embryos aneuploid.

• Reduce miscarriage & twin rate when used with eSET.

• Limitations: invasive, expensive, marginal benefit in young women.
  • Popular “add-ons” (mixed evidence)

• ERA, time-lapse imaging, endometrial scratching, PRP, antioxidants, immunomodulators.

• Need critical appraisal: cost, invasiveness, true benefit vs. placebo.

Panel Discussion – Key Take-home Messages

1. Optimise both egg quality (age factor) and endometrial receptivity for best IVF outcome.

2. Individualise ovarian stimulation by age, BMI, prior response; consider genetic polymorphisms only in select failures.

3. Synchronise follicles in POR patients; long GnRH-agonist still beneficial for some.

4. Maintain strict lab quality: no shortcuts on air handling or equipment.

5. PGT-A useful in selected cases; not a panacea – counselling must be evidence-based.

6. “Signature” protocols welcome but must remain patient-centric and transparent.

7. Success defined not by β-hCG positivity but live-birth (take-home baby) rate; continue meticulous obstetric care after ET.

Ethical, Practical & Educational Implications

• Need for nationwide teacher networks and virtual workshops to offset scarcity of mentors.
• Transparent communication about risks prevents unrealistic expectations and medicolegal issues.
• Importance of ongoing research and sharing of outcomes to refine evidence-based add-ons.

Numerical & Surveillance Cheatsheet

• OHSS moderate–severe: $3.1\% – 8\%$

• Miscarriage in IVF: $15 – 20\%$

• Ectopic after ART: $1.4\%$

• Aspirin dose: $75 – 150\,\text{mg}$ nocte, start ≤$12\,\text{wk}$

• High-risk HDP follow-up: every $3\,\text{wk}$ (24–32 wk) → every $2\,\text{wk}$

• BMI high-risk threshold: >30\,\text{kg/m}^2 (PIH/VTE) or >35\,\text{kg/m}^2 (moderate risk)

• Optimal ET depth: $1.5 – 2\,\text{cm}$ from fundus

Quick Actionable Checklist for Clinicians

[ ] Pre-IVF fitness & risk counselling
[ ] Choose single embryo transfer where feasible
[ ] Low-dose aspirin for qualifying women
[ ] Serial growth, Doppler & BP monitoring
[ ] Vigilance for ectopic/heterotopic gestation
[ ] Laboratory QA: HEPA, low-O₂ incubators, validated consumables
[ ] Individualised stimulation for POR / low AMH
[ ] Evidence-based use of PGT-A & other add-ons
[ ] Emphasise live-birth, not just conception, as success metric